This online-first version will be replaced with a final version when it is included in the issue. The final version may differ in small ways.

Annals of Internal Medicine

REVIEW

Screening for Vitamin D Deficiency: A Systematic Review for the U.S. Preventive Services Task Force

Erin S. LeBlanc, MD, MPH; Bernadette Zakher, MBBS; Monica Daeges, BA; Miranda Pappas, MA; and Roger Chou, MD

Background: Vitamin D deficiency has been associated with adverse health outcomes.

Purpose: To systematically review benefits and harms of vitamin D screening in asymptomatic adults.

Data Sources: Ovid MEDLINE (through the third week of August 2014), Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews.

Study Selection: Randomized trials of screening for and treatment of vitamin D deficiency and case–control studies nested within the Women's Health Initiative.

Data Extraction: One investigator abstracted data, a second reviewed data for accuracy, and 2 investigators independently assessed study quality using predefined criteria.

Data Synthesis: No study examined the effects of vitamin D screening versus no screening on clinical outcomes. Vitamin D treatment was associated with decreased mortality versus placebo or no treatment (11 studies; risk ratio [RR], 0.83 [95% CI, 0.70 to 0.99]), although benefits were no longer seen after trials of institutionalized persons were excluded (8 studies; RR, 0.93 [CI, 0.73 to 1.18]). Vitamin D treatment was associated with possible decreased risk for having at least 1 fall (5 studies; RR, 0.84 [CI, 0.69 to 1.02]) and falls per person (5 studies; incidence rate ratio, 0.66 [CI, 0.50 to 0.88]) but not fractures (5 studies; RR, 0.98 [CI, 0.82 to 1.16]). Vitamin D treatment was not associated with a statistically significant increased risk for serious adverse events (RR, 1.17 [CI, 0.74 to 1.84]).

Limitation: Variability across studies in 25-hydroxyvitamin D assays and baseline levels, treatment doses, use of calcium, and duration of follow-up.

Conclusion: Treatment of vitamin D deficiency in asymptomatic persons might reduce mortality risk in institutionalized elderly persons and risk for falls but not fractures.

Primary Funding Source: Agency for Healthcare Research and Quality.

Ann Intern Med. doi:10.7326/M14-1659 **www.annals.org**

For author affiliations, see end of text.

This article was published online first at www.annals.org on 25 November 2014.

Vitamin D is obtained through food consumption and synthesis in the skin after ultraviolet (UV) B exposure (1). Researchers have reported associations between low 25-hydroxyvitamin D [25-(OH)D] levels and risk for fractures (2–6), falls (7, 8), cardiovascular disease (9–14), colorectal cancer (13–20), diabetes (13, 14, 21–29), depressed mood (13, 14, 30, 31), cognitive decline (13, 14), and death (13, 32).

Vitamin D deficiency is determined by measuring total serum 25-(OH)D concentrations (33). Measuring 25-(OH)D levels is complicated by the presence of multiple assays (34); evidence of intermethod and interlaboratory variability in measurement (35–43); and the lack of an internationally recognized, commutable vitamin D reference standard (44). Efforts to increase standardization are in progress (34, 44).

There is no consensus on optimal 25-(OH)D concentrations. Although experts generally agree that levels lower than 50 nmol/L (20 ng/mL) are associated with bone health (36, 45), disagreement exists about whether optimal 25-(OH)D levels are higher than this threshold (Table 1). According to NHANES (National Health and Nutrition Examination Survey) data from 2001 to 2006, 33% of the U.S. population was at risk for 25-(OH)D levels below 50 nmol/L (20 ng/mL) (47) and 77% had 25-(OH)D levels below 75 nmol/L (30 ng/mL) (48). Risk factors for low vitamin D levels include darker skin pigmentation (33), low vitamin D intake (49–51), little or no UVB exposure (49, 50, 52–54), and obesity (49–51, 55). Older age (49–53), female sex (49, 51, 52), low physical activity (49, 50, 53), low education attainment (48), and low health status (51, 54) were factors also associated with vitamin D deficiency in some studies.

Vitamin D deficiency is treated by increasing dietary intake of food fortified with vitamin D or oral vitamin D treatment. Two commonly available vitamin D treatments (vitamin D_3 [cholecalciferol] and vitamin D_2 [ergocalciferol]) are available in several forms (for example, tablet and gel capsule), dosages (for example, 200 to 500 000 IU) and dosing regimens (for example, daily, weekly, monthly, or yearly) and can be given in combination with oral calcium (56, 57). Potential harms of vitamin D treatment include hypercalcemia, hyperphosphatemia, suppressed parathyroid hormone levels, and hypercalciuria (46, 58, 59). Although very high levels of vitamin D are associated with other potential harms, these events are rare with typical replacement doses (Table 1).

Screening for vitamin D deficiency can identify persons with low levels who might benefit from treatment. This report reviews the current evidence on vitamin D screening in asymptomatic adults to help the U.S. Pre-

See also:

Related article: Ann Intern Med. M14-2450 1
Editorial comment 2
Summary for Patients 3

This online-first version will be replaced with a final version when it is included in the issue. The final version may differ in small ways.

Table 1. Summary of Current Opinions About Appropriate 25-(OH)D Level Cutoffs for Defining Vitamin D Deficiency and Associations Between These Cutoffs and Health Outcomes*

25-(OH)D Level Cutoff	Opinions of Expert and Professional Bodies About Cutoff Levels	Summary of Previous Research on the Associations Between 25-(OH)D Levels and Risk for Health Outcomes	Subgroup Differences for the Associations
<50 nmol/L (<20 ng/mL)	Widely used by researchers and available guidelines as indicative of deficiency	Levels ≥50 nmol/L (≥20 ng/mL) have been associated with decreased risk for fractures, CVD, CRC, diabetes, depressed mood, cognitive decline, and death	Association with fractures and CVD not seen in black persons Association with death seen in black persons Association with falls seen in studies of institutionalized elderly populations Limited data show that association with cognition may be stronger in women
50–75 nmol/L (20–30 ng/mL)	Debate about whether these levels represent deficiency	Levels >60 nmol/L (>24 ng/mL) associated with decreased risk for CVD Levels >75 nmol/L (>30 ng/mL) associated with decreased risk for death and CRC Data conflict about whether levels >75 nmol/L (>30 ng/mL) are associated with decreased risk for fractures	Association with CVD not seen in black persons Association with death seen in black persons
>75–125 nmol/L (>30–50 ng/mL)	General agreement that these levels do not represent deficiency; however, some recommend targeting 25-(OH)D levels to this range because results of 25-(OH)D testing vary	Levels between 87 and 100 nmol/L (35 to 40 ng/mL) may be associated with decreased for death and CRC	NA
>125–499 nmol/L (>50–200 ng/mL)	Debate about whether these levels are associated with adverse health outcomes	Possible U-shaped association between vitamin D levels and risk for death and pancreatic cancer	NA
>499 nmol/L (>200 ng/mL)	These levels are considered toxic	NA	NA

25-(OH)D = 25-hydroxyvitamin D; CRC = colorectal cancer; CVD = cardiovascular disease; NA = not available.
* The appendix of reference 46 contains a full discussion and references.

ventive Services Task Force (USPSTF) develop a recommendation statement. Although the USPSTF has not previously issued recommendations on screening for vitamin D deficiency, it has made recommendations on vitamin D supplementation to prevent adverse health outcomes (for example, falls, fractures, cancer, and cardiovascular disease) in populations not necessarily vitamin D–deficient (that is, general populations who may or may not have been deficient) (60–63).

METHODS

Scope of the Review

We developed a review protocol and analytic framework (**Appendix Figure 1**, available at www.annals.org) that included the following key questions:

1. Is there direct evidence that screening for vitamin D deficiency results in improved health outcomes?

1a. Are there differences in screening efficacy between patient subgroups?

2. What are the harms of screening (for example, risk for procedure, false positives, or false negatives)?

3. Does treatment of vitamin D deficiency using vitamin D lead to improved health outcomes?

3a. Are there differences in efficacy between patient subgroups?

4. What are the adverse effects of treatment of vitamin D deficiency using vitamin D?

4a. Are there differences in adverse effects between patient subgroups?

Detailed methods and data for this review are contained in the full report, including search strategies, inclusion criteria, abstraction and quality rating tables, and contextual questions (46). We developed our protocol using a standardized process after gathering input from experts and the public. The analytic framework focuses on direct evidence that screening for vitamin D deficiency improves important health outcomes (for example, death, falls, fractures, functional status, or risk for cancer versus not screening. Further, the framework details evidence that treatment in persons found to have vitamin D deficiency is associated with improved health outcomes, harms resulting from screening or subsequent treatment, and how effects of screening and treatment vary in subgroups defined by demographic and other factors (for example, body mass index, UV exposure, and institutionalized status). We did not review the accuracy of vitamin D testing because of the lack of an accepted reference standard and studies reporting diagnostic accuracy.

For the purposes of this report, the term "vitamin D–deficient" refers to populations in which at least 90% of persons have 25-(OH)D levels of 75 nmol/L (30 ng/mL) or less. For studies that did not restrict enrollment to persons with 25-(OH)D levels of 75 nmol/L (30 ng/mL), we used the mean 25-(OH)D level plus the SD multiplied by 1.282 to approximate the 90th percentile to determine whether this level was at or below the 75-nmol/L (30-ng/mL) threshold. Because of uncertainty

This online-first version will be replaced with a final version when it is included in the issue. The final version may differ in small ways.

about what 25-(OH)D level constitutes deficiency, we stratified studies according to whether at least 90% of persons had levels less than 50 nmol/L ("<20 ng/mL" in this report) or at least 90% had levels less than 75 nmol/L (30 ng/mL) with at least 10% greater than 50 nmol/L (20 ng/mL) ("≤75 nmol/L [≤30 ng/mL]" in this report).

Data Sources and Searches

A research librarian searched Ovid MEDLINE (1946 through the third week of August 2014), Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews (through August 2014). We supplemented our electronic searches by reviewing reference lists of retrieved articles.

Study Selection

At least 2 reviewers independently evaluated each study to determine inclusion eligibility. For screening studies, we included randomized, controlled trials (RCTs) of screening for vitamin D deficiency versus no screening in healthy, asymptomatic adults (aged ≥18 years). For studies of the effectiveness of vitamin D treatment, we included RCTs of vitamin D treatment with or without calcium versus placebo or no treatment in vitamin D–deficient persons that reported health outcomes after at least 8 weeks of treatment. Because the Women's Health Initiative (WHI) is the largest RCT about vitamin D (64), we included data from nested case–control studies of WHI participants with known 25-(OH)D status.

We included English-language articles only and excluded studies published only as abstracts. We included studies conducted in the United States, Canada, United Kingdom, and other geographic settings generalizable to the United States. We excluded studies that specifically targeted populations with symptoms or conditions associated with vitamin D deficiency (for example, osteoporosis, history of nontraumatic fractures, or history of falls) or with medical conditions that increase a person's risk for deficiency (such as liver, kidney, or malabsorptive disease) because screening and treatment of vitamin D deficiency could be a component of medical management in these conditions. The summary of evidence search and selection is shown in Appendix Figure 2 (available at www.annals.org).

Data Abstraction and Quality Rating

One investigator abstracted details about the study design, patient population, setting, screening method, interventions, analysis, follow-up, and results. A second investigator reviewed data for accuracy. Two investigators independently applied USPSTF criteria (65) to rate the quality of each study as good, fair, or poor. We resolved discrepancies through a consensus process. We excluded from data synthesis studies rated as poor quality. Those studies had 1 or more fatal flaws, including inadequate randomization or lack of intervention fidelity combined with postrandomization exclusions, high rates of withdrawals, and unclear randomization.

Data Synthesis and Analysis

We assessed the aggregate internal validity (quality) of the body of evidence for each key question (good, fair, or poor) using methods developed by the USPSTF on the basis of the number, quality, and size of studies; consistency of results; and directness of evidence (65).

We conducted meta-analyses to calculate risk ratios (RRs) using the DerSimonian–Laird random-effects model (Review Manager, version 5.2; Cochrane Collaboration). Analyses were based on total follow-up (including time after discontinuation of vitamin D treatment). For falls per person, we calculated incidence rate ratios and assumed equal mean length of follow-up across treatment groups if these data were not reported. For analyses with between-study heterogeneity, we conducted sensitivity analyses using profile likelihood random-effects models (66). Rate ratio analysis and analyses using the profile likelihood model were done with Stata, version 12.0 (StataCorp). We performed sensitivity analyses restricted to RCTs, excluding the WHI subanalyses, and used odds ratios rather than RRs.

We assessed statistical heterogeneity using the chi-square test and I^2 statistic (67). For all analyses, we stratified results by serum baseline 25-(OH)D level (<50 nmol/L [<20 ng/mL] vs. ≤75 nmol/L [≤30 ng/mL]). We performed additional analyses in which trials were stratified by institutionalized status, treatment regimen (vitamin D alone [vitamin D vs. placebo or no treatment, or vitamin D plus calcium vs. calcium alone] or vitamin D combined with calcium [vitamin D plus calcium vs. placebo or no treatment]), vitamin D dose (≤400 vs. >400 IU/d), duration of follow-up (≤12 vs. >12 months), and participant mean age (≤70 vs. >70 years).

Role of the Funding Source

This research was funded by the Agency for Healthcare Research and Quality (AHRQ) under a contract to support the work of the USPSTF. Investigators worked with USPSTF members and AHRQ staff to develop the scope, analytic framework, and key questions for this review. AHRQ had no role in study selection, quality assessment, or synthesis. AHRQ staff provided project oversight, reviewed the report to ensure that the analysis met methodological standards, and distributed the draft for peer review. The investigators are solely responsible for the content and the decision to submit it for publication.

RESULTS

No study evaluated clinical outcomes or harms in persons screened versus not screened for vitamin D deficiency.

Effectiveness of Vitamin D Treatment

Seven trials evaluated the effectiveness of vitamin D treatment (with or without calcium) in populations with at least 90% of persons with 25-(OH)D levels less than 50 nmol/L (20 ng/mL) (68–74). Nine trials and 1 nested case–control study evaluated effectiveness in

This online-first version will be replaced with a final version when it is included in the issue. The final version may differ in small ways.

populations with at least 90% of their population with levels of 75 nmol/L (30 ng/mL) or less (75–90) (**Appendix Table**, available at www.annals.org). The mean age of the participants in these trials ranged from 37 to 85 years, and more than 70% of the studies enrolled only women. Mean body mass indices ranged from 24 to 36 kg/m^2. The included studies were population-based or were conducted within outpatient clinics, academic institutions, and nursing or residential homes for elderly adults (considered institutionalized) in the United States or Europe. Ultraviolet exposure was not well-quantified in any study, and only 6 studies (64, 70, 71, 75, 82, 85) reported race. Of these, 1 study restricted enrollment to African Americans (70) and 83% to 100% of participants in the remaining 6 studies were white. Studies examined vitamin D_3 at dosages ranging from 400 to 4800 IU/d or 8400 to 50 000 IU/wk. Five studies examined vitamin D_3 treatment coadministered with calcium (1000 to 1200 mg/d), and 12 examined vitamin D_3 treatment alone. Study duration ranged from 2 months to 7 years, and the assays these studies used to measure 25-(OH)D varied. Methodological shortcomings among these studies included unclear randomization and allocation concealment methods or blinding. Some studies had unclear intervention fidelity (that is, they did not record postintervention 25-[OH]D levels) or reported high attrition (>20%).

Mortality

One good-quality trial, 9 fair-quality trials, and 1 fair-quality nested case–control study reported effects of vitamin D treatment (dose, 400 IU/d to 40 000 IU/wk) on mortality in vitamin D–deficient populations (n = 4126) (68–73, 77, 80, 82, 83, 89). Mortality was not a primary outcome in any study. No individual study reported a statistically significant reduction in mortality with vitamin D treatment versus placebo or no treatment, although the estimates were often imprecise because of very few events (68, 70–73, 77, 82). When data were pooled, vitamin D treatment with or without calcium was associated with decreased risk for mortality versus placebo or no treatment (RR, 0.83 [95% CI, 0.70 to 0.99]; I^2 = 0%; absolute risk difference ranged from a reduction of 6 percentage points to an increase of 2 percentage points) (**Appendix Figure 3**, available at www.annals.org).

When analyses were stratified by institutionalized status, the risk reduction was limited to studies of older, institutionalized persons (3 studies; RR, 0.72 [CI, 0.56 to 0.94]; I^2 = 0%; absolute risk reduction, 4 to 6 percentage points) (**Figure 1**) (69, 80, 83). The effect was not present in noninstitutionalized populations (8 studies; RR, 0.93 [CI, 0.73 to 1.18]; I^2 = 0%) (68, 70–73, 77, 82, 89). In additional sensitivity analyses, the reduction in mortality occurred when pooling studies with more than 12 months' duration and whose population had a mean age greater than 70 years. Stratification by baseline 25-(OH)D level, calcium use, or vitamin D dosage did not affect risk estimates.

Fracture Risk

Four fair-quality trials and 1 nested case–control study examined the effects of 2 months to 7 years of vitamin D treatment (with or without calcium), 400 to 800 IU/d, on the risk for any type of fracture in vitamin D–deficient persons (n = 3551) (69, 74, 81, 84, 88). No individual study reported a statistically significant reduction in fracture risk with vitamin D treatment, including the largest study—a case–control analysis nested within the WHI calcium-vitamin D trial (88). The pooled estimate was close to 1 (5 trials; RR, 0.98 [CI, 0.82 to 1.16]; I^2 = 32%) (**Figure 2**, *top*). Sensitivity analyses resulted in similar findings of no effect and did not decrease heterogeneity. Results were similar when only hip fracture risk was examined (4 trials; RR, 0.96 [CI, 0.72 to 1.29]; I^2 = 46%) (**Figure 2**, *bottom*) (69, 74, 81, 88).

Fall Risk

Five fair-quality trials examined the effects of 2 to 36 months of vitamin D treatment (with or without calcium), 800 IU/d, compared with control, on the risk for experiencing at least 1 fall (n = 1677) (69, 74, 76, 78, 84). Although the trials did not specifically recruit participants at high risk for frailty or those who had prior falls, these studies included persons who may have been at risk for falls based on older age (mean age >70 years) (69, 74, 76, 84), institutionalized status (69, 76), mobility problems (69, 76), or multiple comorbid conditions (69, 74, 76). In 2 studies, a proportion of patients had a history of falls (69, 76). Although the overall summary RR for experiencing at least 1 fall with vitamin D treatment was consistent with reduced risk (5 trials; pooled RR, 0.84 [CI, 0.69 to 1.02]) (**Figure 3**); the result was not statistically significant, and heterogeneity was high (I^2 = 70%). Sensitivity analyses based on institutionalized status, baseline 25-(OH)D level, vitamin D dosage, study duration, and age did not reduce heterogeneity and resulted in similar estimates. Heterogeneity, however, was reduced to 0 when we excluded 2 trials of cotreatment with vitamin D and calcium (69, 78). Vitamin D treatment alone was associated with decreased risk for experiencing at least 1 fall (3 trials; RR, 0.65 [CI, 0.52 to 0.81]; I^2 = 0%) (74, 76, 84).


Five fair-quality trials examined the effect of vitamin D treatment (with or without calcium), 400 to 1000 IU/d, compared with control on the number of falls per person (n = 1399) (74, 76, 78, 84, 85). Vitamin D treatment was associated with a significant reduction in the number of falls per person versus placebo or no treatment (5 trials; incidence rate ratio, 0.66 [CI, 0.50 to 0.88]; I^2 = 65%) (**Figure 4**). Although statistical heterogeneity was present, all estimates favored vitamin D treatment. Sensitivity analyses did not affect findings.

Other Health Outcomes

One to 2 studies examined the effects of vitamin D (with or without calcium) on cancer risk (86, 90), type 2 diabetes mellitus risk (85, 87), psychosocial functioning and psychosocial disability (79, 91), and physical func-

This online-first version will be replaced with a final version when it is included in the issue. The final version may differ in small ways.

Figure 1. Meta-analysis of effects of vitamin D treatment on mortality, by institutionalized status.



* This is a nested case-control study from the Women's Health Initiative calcium-vitamin D trial (64).

tioning (73). Findings either were mixed or showed no effect on these health outcomes.

Subgroup Effects

None of the included trials were designed or powered to evaluate potential subgroup effects based on factors, such as sex, race, body mass index, or UV exposure. Data suggesting benefits of vitamin D treatment on mortality and falls seemed to be primarily limited to trials of older, often institutionalized, European women (69, 80, 83).


Harms of Vitamin D Treatment


Twenty-four trials evaluated harms associated with vitamin D treatment (with or without calcium) in vitamin D–deficient populations aged 31 to 85 years (n = 4722) (**Appendix Table**) (68–73, 75–77, 79, 80, 82, 83, 85, 92–103). Vitamin D treatment (mostly D_3 formulation) was given at doses of 400 to 7000 IU/d or 8400 to 54 000 IU/wk for 6 weeks to 4 years. Nineteen trials evaluated the vitamin D treatment alone, and 5 evaluated vitamin D with calcium. Methodological shortcomings included unclear randomization procedure; inadequate or unclear masking of assessors, providers, or participants; high attrition; and no clear statement that adverse events were a prespecified outcome.

We found no difference between treatment with vitamin D and placebo or no treatment in risk for any adverse event (n = 1332; 7 trials), serious adverse events (n = 1401; 7 trials; RR, 1.17 [CI, 0.74 to 1.84]), withdrawals due to adverse events (n = 938; 5 trials; RR, 0.90 [CI, 0.36 to 2.24]), hypercalcemia (n = 3172; 16 studies; RR, 1.05 [CI, 0.57 to 1.94]), kidney stones (n = 1608; 7 trials, with no kidney stones reported in any trial), or gastrointestinal symptoms (n = 1201; 4 trials; RR, 0.84 [CI, 0.44 to 1.58]). The studies were not de-

This online-first version will be replaced with a final version when it is included in the issue. The final version may differ in small ways.

Figure 2. Meta-analysis of effects of vitamin D treatment on risk for any fracture (*top*) or hip fracture (*bottom*).






To convert ng/mL to nmol/L, divide by 0.40. 25-(OH)D = serum 25-hydroxyvitamin D.
* ≥90% of study participants had 25-(OH)D levels <20 ng/mL.
† Included an institutionalized population.
‡ ≥90% of study participants had 25-(OH)D levels ≤30 ng/mL, with ≥10% with 25-(OH)D levels ≥20 ng/mL.
§ This is a nested case–control study from the Women's Health Initiative calcium-vitamin D trial (64).

This online-first version will be replaced with a final version when it is included in the issue. The final version may differ in small ways.

Figure 3. Meta-analysis of effects of vitamin D treatment on risk for falls.



To convert ng/mL to nmol/L, divide by 0.40. 25-(OH)D = serum 25-hydroxyvitamin D.
* ≥90% of study participants had 25-(OH)D levels <20 ng/mL.
† Included an institutionalized population.
‡ ≥90% of study participants had 25-(OH)D levels ≤30 ng/mL, and ≥10% had 25-(OH)D levels ≥20 ng/mL.
§ The calculated risk ratio is different from the one reported by the study.

signed to evaluate whether harms differ according to demographic or other clinical characteristics.


Discussion

The evidence reviewed in this report is summarized in Table 2. We found no direct evidence on effects of screening for vitamin D deficiency versus no screening on clinical outcomes. In persons with low vitamin D levels, vitamin D treatment was associated with decreased risk for death, but effects were no longer present when 3 trials of older institutionalized women were excluded from the analysis (69, 80, 83). Vitamin D treatment was associated with a nonsignificant reduction in the risk for experiencing 1 or more falls and a significantly reduced overall burden of falls, which is measured by the number of falls per person. This potential discrepancy seems largely attributable to 1 trial that was conducted in an institutionalized population with a high comorbidity burden; the trial reported a rate ratio for falls per person as its primary outcome that was lower than the risk for experiencing at least 1 fall (0.46 [CI, 0.28 to 0.76] and 0.75 [CI, 0.41 to 1.37], respectively) (76). The risk estimates were similar in 3 other trials that reported both risk for falls and the rate of falls per person (74, 78, 84). Data were limited (≤2 studies) on the effect of vitamin D on other outcomes, such as cancer risk, type 2 diabetes mellitus risk, psychosocial functioning, disability, and physical functioning. Vitamin D treatment did not seem to be associated with increased risk for harms, although few trials were designed to specifically address harms and harms reporting was often suboptimal. Evidence to evaluate subgroup effects on the basis of factors, such as race, sex, age, or risk factors for vitamin D deficiency, was very limited. This precludes us from drawing reliable conclusions.

An important limitation of the evidence is that no study specifically evaluated the effect of treatment of screen-detected vitamin D deficiency, which potentially limits their applicability to screening settings. Although we excluded studies that selected patients with conditions and outcomes associated with vitamin D deficiency, symptoms were not reported, which makes it difficult to know whether patients were truly asymptomatic. In addition, baseline 25-(OH)D levels, dosages

This online-first version will be replaced with a final version when it is included in the issue. The final version may differ in small ways.

Figure 4. Meta-analysis of effects of vitamin D treatment on the number of falls per person.



To convert ng/mL to nmol/L, divide by 0.40. 25-(OH)D = serum 25-hydroxyvitamin D; PY = person-year.
* ≥90% of study participants had 25-(OH)D levels <20 ng/mL.
† Included an institutionalized population.

used, use of calcium cosupplementation, and duration of follow-up varied among these studies. Sensitivity and stratified analyses on these factors, however, did not affect conclusions.

The included studies also used various vitamin D assays, and we cannot precisely determine how assay variability affected findings given the lack of a reference standard to estimate diagnostic accuracy. In general, differential classification due to assay variability is likely to affect persons with levels close to the threshold used to define vitamin D deficiency. In studies of vitamin D treatment, misclassification would attenuate estimates of treatment benefit because some persons who are not vitamin D–deficient would be classified and treated as such. These patients would also be subjected to unnecessary treatment and associated harms.

For this review, we required that participants in treatment studies be vitamin D–deficient. Previous USPSTF reviews on vitamin D evaluated vitamin D supplementation in persons who were or were not vitamin D–deficient and could be at risk for a particular condition or outcome (104–106). On the basis of these reviews, the USPSTF made recommendations about vitamin D supplementation in persons whose deficiency status is unknown or are at risk for particular conditions. The USPSTF recommended vitamin D supplementation for community-dwelling adults aged 65 years or older at increased risk for falls regardless of 25-(OH)D status (60). The USPSTF recommended against low-dose supplementation with vitamin D (≤400 IU) and calcium (≤1000 mg) to reduce fracture risk in noninstitutionalized populations and concluded that data on the effects of higher doses were insufficient (62). The USPSTF also concluded that data were insufficient about the effects of vitamin D supplementation on cardiovascular disease and cancer risk (63). Previous reviews for the USPSTF found harms were generally low (104–106). Prior systematic reviews noted that the WHI calcium-vitamin D trial found a significantly increased risk for kidney stones (64). We did not include these results from the WHI because the risk for stones was not reported for women with low 25-(OH)D levels.

Our review had limitations. We excluded non–English-language articles and studies published only as abstracts, and we could not formally assess for publication bias because of the small number of studies. Some pooled analyses were based on small numbers of studies or were characterized by the presence of statistical heterogeneity. In these cases, the DerSimonian–Laird random-effects model may result in CIs that are too narrow (107). Therefore, we performed sensitivity analyses using the profile likelihood method that resulted in similar findings. We also focused on the effects of vitamin D treatment in patients similar to those who would be identified through a screening program. As such, we excluded studies that targeted populations for which vitamin D might be considered a treatment option or with particular medical conditions associated with vitamin D deficiency, even if the participants had low 25-(OH)D levels. On the basis of these criteria, we excluded trials that required participants to have osteoporosis or osteopenia (4 studies [108–111]), risk factors for falls (5 studies [112–116]), prediabetes (1 study [117]), heart failure (2 studies [118, 119]), or tuberculosis (1 study [120]). In those trials, vitamin D treatment did not reduce fracture risk in those with a history of fractures. Treatment reduced risk for falls in persons who had a history of falls (112) but not in those with a recent hip fracture (111) or at least 1 health problem or functional limitation (114).

This online-first version will be replaced with a final version when it is included in the issue. The final version may differ in small ways.

Table 2. Summary of Evidence for Screening for Vitamin D Deficiency in Asymptomatic Adults

Key Question	Studies, *n*	Type of Studies	Overall Quality	Limitations	Consistency	Applicability	Summary of Findings
1. Is there direct evidence that screening for vitamin D deficiency results in improved health outcomes? 1a. Are there differences in screening efficacy between patient subgroups?	0	NA	NA	NA	NA	NA	NA
2. What are the harms of screening (e.g., risk for procedure, false positives, and false negatives)?	0	NA	NA	NA	NA	NA	NA
3. Does treatment of vitamin D deficiency using vitamin D lead to improved health outcomes?	17	RCTs and nested case–control studies	Fair	Few studies addressed each outcome; many studies reported few events or were underpowered; and variability in baseline 25-(OH)D levels, doses of vitamin D, use of calcium cosupplementation, and length of follow-up	Moderate	Studies mostly done in older, white, U.S. or European women	Vitamin D treatment (with or without calcium) was associated with a decreased risk for death (11 studies; pooled RR, 0.83 [95% CI, 0.70–0.99]); risk reduction limited to studies of older, institutionalized persons (3 trials; pooled RR, 0.72 [CI, 0.56–0.94]). Vitamin D treatment was not associated with decreased risk for falling (5 studies; pooled RR, 0.84 [CI, 0.69–1.02]) but was associated with a lower rate of falls per person (pooled rate ratio, 0.66 [CI, 0.50–0.88]). Vitamin D treatment was not associated with a decreased risk for fractures (5 studies; pooled RR, 0.98 [CI, 0.82–1.16]). Limited data (≤2 studies) on risk for cancer and type 2 diabetes, psychosocial and physical functioning, and disability, but generally no associations with vitamin D treatment were seen.
3a. Are there differences in efficacy between patient subgroups?	0	NA	NA	NA	NA	NA	NA
4. What are the adverse effects of treatment of vitamin D deficiency using vitamin D?	24*	RCTs and cohort studies	Fair	Few studies prespecified harms outcomes; studies were not designed to address harms; and variability in baseline 25-(OH)D levels, doses of vitamin D, use of calcium cosupplementation, and length of follow-up	High	Only 7 studies were done in the United States, and only 3 of these reported populations having a significant percentage of nonwhite participants	Vitamin D treatment (with or without calcium) was not associated with increased adverse events.
4a. Are there differences in adverse effects between patient subgroups?	0	NA	NA	NA	NA	NA	NA

25-(OH)D = 25-hydroxyvitamin D; NA = not applicable; RCT = randomized, controlled trial; RR = risk ratio.
* Includes 2 poor-quality trials.

This online-first version will be replaced with a final version when it is included in the issue. The final version may differ in small ways.

A trial of screening for vitamin D in a diverse population would be the ideal way to evaluate benefits and harms. Greater standardization in vitamin D assays is needed for this study to be most informative. In addition, given the lack of consensus about what level of 25-(OH)D (for example, <50 vs. <75 nmol/L [<20 vs. <30 ng/mL]) defines deficiency (36, 45, 121–124), future studies of treatment should stratify results according to the baseline vitamin D level. Definitions of vitamin D deficiency may need to take into account potential racial differences in total 25-(OH)D levels relative to bioavailable levels (99).

In conclusion, no study directly examined the benefits and harms of screening for vitamin D deficiency. Based on limited evidence in persons not known to have conditions associated with vitamin D deficiency, treating this deficiency with vitamin D may be associated with decreased risk for death in institutionalized elderly adults and a reduction in the average number of falls but not fractures. Future research is needed to reduce assay variability; determine appropriate thresholds for vitamin D deficiency; and clarify effects of screening, subsequent treatment, and the subpopulations most likely to benefit.

From Center for Health Research, Kaiser Permanente Northwest, Pacific Northwest Evidence-based Practice Center, Oregon Health & Science University, Portland, Oregon.

Disclaimer: The findings and conclusions in this document are those of the authors, who are responsible for its content, and do not necessarily represent the views of AHRQ. No statement in this report should be construed as an official position of AHRQ or the U.S. Department of Health and Human Services.

Acknowledgment: The authors thank Andrew Hamilton, MLS, MS, for conducting literature searches; Rongwei Fu, PhD, for statistical assistance; and Spencer Dandy, BS, for assistance with drafting this manuscript at the Oregon Health & Science University. The authors also thank Kevin Lutz, MFA, at the Center for Health Research for editorial assistance; AHRQ Medical Officers Robert McNellis, MPH, PA, Tina Fan, MD, MPH, and Tess Miller, DrPH; and U.S. Preventive Services Task Force Leads Linda Baumann, PhD, RN, Doug Owens, MD, MS, and Albert Siu, MD, MSPH.

Grant Support: By the Agency for Healthcare Research and Quality (contract number HSSA 290-2007-10057-I).

Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M14-1659.

Requests for Single Reprints: Erin S. LeBlanc, MD, MPH, Center for Health Research, Kaiser Permanente, 3800 North Interstate Avenue, Portland, OR 97227; e-mail, erin.s.leblanc@kpchr.org.

Current author addresses and author contributions are available at www.annals.org.

References

1. **Mithal A, Wahl DA, Bonjour JP, Burckhardt P, Dawson-Hughes B, Eisman JA, et al; IOF Committee of Scientific Advisors (CSA) Nutrition Working Group.** Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int. 2009;20:1807-20. [PMID: 19543765] doi:10.1007/s00198-009-0954-6

2. **Holvik K, Ahmed LA, Forsmo S, Gjesdal CG, Grimnes G, Samuelsen SO, et al.** Low serum levels of 25-hydroxyvitamin D predict hip fracture in the elderly: a NOREPOS study. J Clin Endocrinol Metab. 2013;98:3341-50. [PMID: 23678033] doi:10.1210/jc.2013-1468

3. **Cauley JA, Parimi N, Ensrud KE, Bauer DC, Cawthon PM, Cummings SR, et al; Osteoporotic Fractures in Men (MrOS) Research Group.** Serum 25-hydroxyvitamin D and the risk of hip and nonspine fractures in older men. J Bone Miner Res. 2010;25:545-53. [PMID: 19775201] doi:10.1359/jbmr.090826

4. **Looker AC, Mussolino ME.** Serum 25-hydroxyvitamin D and hip fracture risk in older U.S. white adults. J Bone Miner Res. 2008;23:143-50. [PMID: 17907920]

5. **Cauley JA, Lacroix AZ, Wu L, Horwitz M, Danielson ME, Bauer DC, et al.** Serum 25-hydroxyvitamin D concentrations and risk for hip fractures. Ann Intern Med. 2008;149:242-50. [PMID: 18711154]

6. **Cauley JA, Danielson ME, Boudreau R, Barbour KE, Horwitz MJ, Bauer DC, et al.** Serum 25-hydroxyvitamin D and clinical fracture risk in a multiethnic cohort of women: the Women's Health Initiative (WHI). J Bone Miner Res. 2011;26:2378-88. [PMID: 21710614] doi:10.1002/jbmr.449

7. **Chung M, Balk EM, Brendel M, Ip S, Lau J, Lee J, et al.** Vitamin D and Calcium: A Systematic Review of Health Outcomes. Evidence Report/Technology Assessment no. 183. (Prepared by Tufts Evidence-based Practice Center under contract no. 290-2007-10055-I.) AHRQ publication no. 09-E015. Rockville, MD: Agency for Healthcare Research and Quality; 2009. Accessed at www.ahrq.gov/downloads/pub/evidence/pdf/vitadcal/vitadcal.pdf on 17 January 2014.

8. **Cranney A, Horsley T, O'Donnell S, Weiler H, Puil L, Ooi D, et al.** Effectiveness and safety of vitamin D in relation to bone health. Evid Rep Technol Assess (Full Rep). 2007:1-235. [PMID: 18088161]

9. **Pittas AG, Chung M, Trikalinos T, Mitri J, Brendel M, Patel K, et al.** Systematic review: vitamin D and cardiometabolic outcomes. Ann Intern Med. 2010;152:307-14. [PMID: 20194237] doi:10.7326/0003-4819-152-5-201003020-00009

10. **Wang L, Song Y, Manson JE, Pilz S, März W, Michaëlsson K, et al.** Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: a meta-analysis of prospective studies. Circ Cardiovasc Qual Outcomes. 2012;5:819-29. [PMID: 23149428] doi:10.1161/CIRCOUTCOMES.112.967604

11. **Brøndum-Jacobsen P, Benn M, Jensen GB, Nordestgaard BG.** 25-hydroxyvitamin d levels and risk of ischemic heart disease, myocardial infarction, and early death: population-based study and meta-analyses of 18 and 17 studies. Arterioscler Thromb Vasc Biol. 2012;32:2794-802. [PMID: 22936341] doi:10.1161/ATVBAHA.112.248039

12. **Sun Q, Pan A, Hu FB, Manson JE, Rexrode KM.** 25-Hydroxyvitamin D levels and the risk of stroke: a prospective study and meta-analysis. Stroke. 2012;43:1470-7. [PMID: 22442173] doi:10.1161/STROKEAHA.111.636910

13. **Autier P, Boniol M, Pizot C, Mullie P.** Vitamin D status and ill health: a systematic review. Lancet Diabetes Endocrinol. 2014;2:76-89. [PMID: 24622671] doi:10.1016/S2213-8587(13)70165-7

14. **Theodoratou E, Tzoulaki I, Zgaga L, Ioannidis JP.** Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. BMJ. 2014;348:g2035. [PMID: 24690624] doi:10.1136/bmj.g2035

15. **Yin L, Raum E, Haug U, Arndt V, Brenner H.** Meta-analysis of longitudinal studies: serum vitamin D and prostate cancer risk. Cancer Epidemiol. 2009;33:435-45. [PMID: 19939760] doi:10.1016/j.canep.2009.10.014

16. **Grant WB.** Relation between prediagnostic serum 25-hydroxyvitamin D level and incidence of breast, colorectal, and other

This online-first version will be replaced with a final version when it is included in the issue. The final version may differ in small ways.

cancers. J Photochem Photobiol B. 2010;101:130-6. [PMID: 20570169] doi:10.1016/j.jphotobiol.2010.04.008
17. **Gandini S, Boniol M, Haukka J, Byrnes G, Cox B, Sneyd MJ, et al.** Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer. 2011;128:1414-24. [PMID: 20473927] doi: 10.1002/ijc.25439
18. **Lee JE, Li H, Chan AT, Hollis BW, Lee IM, Stampfer MJ, et al.** Circulating levels of vitamin D and colon and rectal cancer: the Physicians' Health Study and a meta-analysis of prospective studies. Cancer Prev Res (Phila). 2011;4:735-43. [PMID: 21430073] doi: 10.1158/1940-6207.CAPR-10-0289
19. **Gorham ED, Garland CF, Garland FC, Grant WB, Mohr SB, Lipkin M, et al.** Optimal vitamin D status for colorectal cancer prevention: a quantitative meta analysis. Am J Prev Med. 2007;32:210-6. [PMID: 17296473]
20. **World Health Organization; International Agency for Research on Cancer.** Vitamin D and Cancer. IARC Working Group Reports Volume 5. Lyon, France: International Agency for Research on Cancer; 2008. Accessed at www.iarc.fr/en/publications/pdfs-online/wrk/wrk5/Report_VitD.pdf on 5 November 2014.
21. **Mattila C, Knekt P, Männistö S, Rissanen H, Laaksonen MA, Montonen J, et al.** Serum 25-hydroxyvitamin D concentration and subsequent risk of type 2 diabetes. Diabetes Care. 2007;30:2569-70. [PMID: 17626891]
22. **Knekt P, Laaksonen M, Mattila C, Härkänen T, Marniemi J, Heliövaara M, et al.** Serum vitamin D and subsequent occurrence of type 2 diabetes. Epidemiology. 2008;19:666-71. [PMID: 18496468] doi:10.1097/EDE.0b013e318176b8ad
23. **González-Molero I, Rojo-Martínez G, Morcillo S, Gutiérrez-Repiso C, Rubio-Martín E, Almaraz MC, et al.** Vitamin D and incidence of diabetes: a prospective cohort study. Clin Nutr. 2012;31:571-3. [PMID: 22204964] doi:10.1016/j.clnu.2011.12.001
24. **Pittas AG, Sun Q, Manson JE, Dawson-Hughes B, Hu FB.** Plasma 25-hydroxyvitamin D concentration and risk of incident type 2 diabetes in women. Diabetes Care. 2010;33:2021-3. [PMID: 20805275] doi:10.2337/dc10-0790
25. **Song Y, Wang L, Pittas AG, Del Gobbo LC, Zhang C, Manson JE, et al.** Blood 25-hydroxy vitamin D levels and incident type 2 diabetes: a meta-analysis of prospective studies. Diabetes Care. 2013;36:1422-8. [PMID: 23613602] doi:10.2337/dc12-0962
26. **Tsur A, Feldman BS, Feldhammer I, Hoshen MB, Leibowitz G, Balicer RD.** Decreased serum concentrations of 25-hydroxycholecalciferol are associated with increased risk of progression to impaired fasting glucose and diabetes. Diabetes Care. 2013;36:1361-7. [PMID: 23393216] doi:10.2337/dc12-1050
27. **Schöttker B, Herder C, Rothenbacher D, Perna L, Müller H, Brenner H.** Serum 25-hydroxyvitamin D levels and incident diabetes mellitus type 2: a competing risk analysis in a large population-based cohort of older adults. Eur J Epidemiol. 2013;28:267-75. [PMID: 23354985] doi:10.1007/s10654-013-9769-z
28. **Husemoen LL, Skaaby T, Thuesen BH, Jørgensen T, Fenger RV, Linneberg A.** Serum 25(OH)D and incident type 2 diabetes: a cohort study. Eur J Clin Nutr. 2012;66:1309-14. [PMID: 23031851] doi: 10.1038/ejcn.2012.134
29. **Forouhi NG, Ye Z, Rickard AP, Khaw KT, Luben R, Langenberg C, et al.** Circulating 25-hydroxyvitamin D concentration and the risk of type 2 diabetes: results from the European Prospective Investigation into Cancer (EPIC)-Norfolk cohort and updated meta-analysis of prospective studies. Diabetologia. 2012;55:2173-82. [PMID: 22526608] doi:10.1007/s00125-012-2544-y
30. **Milaneschi Y, Shardell M, Corsi AM, Vazzana R, Bandinelli S, Guralnik JM, et al.** Serum 25-hydroxyvitamin D and depressive symptoms in older women and men. J Clin Endocrinol Metab. 2010;95:3225-33. [PMID: 20444911] doi:10.1210/jc.2010-0347
31. **Maddock J, Berry DJ, Geoffroy MC, Power C, Hyppönen E.** Vitamin D and common mental disorders in mid-life: cross-sectional and prospective findings. Clin Nutr. 2013;32:758-64. [PMID: 23395104] doi:10.1016/j.clnu.2013.01.006
32. **Chowdhury R, Kunutsor S, Vitezova A, Oliver-Williams C, Chowdhury S, Kiefte-de-Jong JC, et al.** Vitamin D and risk of cause specific death: systematic review and meta-analysis of observational cohort and randomised intervention studies. BMJ. 2014;348:g1903. [PMID: 24690623] doi:10.1136/bmj.g1903
33. **Holick MF.** Vitamin D deficiency. N Engl J Med. 2007;357:266-81. [PMID: 17634462]
34. **Fraser WD, Milan AM.** Vitamin D assays: past and present debates, difficulties, and developments. Calcif Tissue Int. 2013;92:118-27. [PMID: 23314742] doi:10.1007/s00223-012-9693-3
35. **Institute of Medicine.** 2011 Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academies Pr; 2011.
36. **Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al; Endocrine Society.** Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911-30. [PMID: 21646368] doi:10.1210/jc.2011-0385
37. **Holmes EW, Garbincius J, McKenna KM.** Analytical variability among methods for the measurement of 25-hydroxyvitamin D: still adding to the noise. Am J Clin Pathol. 2013;140:550-60. [PMID: 24045553] doi:10.1309/AJCPU2SKW1TFKSWY
38. **Lai JK, Lucas RM, Banks E, Ponsonby AL; Ausimmune Investigator Group.** Variability in vitamin D assays impairs clinical assessment of vitamin D status. Intern Med J. 2012;42:43-50. [PMID: 21395958] doi:10.1111/j.1445-5994.2011.02471.x
39. **Bedner M, Lippa KA, Tai SS.** An assessment of 25-hydroxyvitamin D measurements in comparability studies conducted by the Vitamin D Metabolites Quality Assurance Program. Clin Chim Acta. 2013;426:6-11. [PMID: 23978484] doi:10.1016/j.cca.2013.08.012
40. **Cashman KD, Kiely M, Kinsella M, Durazo-Arvizu RA, Tian L, Zhang Y, et al.** Evaluation of Vitamin D Standardization Program protocols for standardizing serum 25-hydroxyvitamin D data: a case study of the program's potential for national nutrition and health surveys. Am J Clin Nutr. 2013;97:1235-42. [PMID: 23615829] doi: 10.3945/ajcn.112.057182
41. **Wagner D, Hanwell HE, Vieth R.** An evaluation of automated methods for measurement of serum 25-hydroxyvitamin D. Clin Biochem. 2009;42:1549-56. [PMID: 19631201] doi:10.1016/j.clinbiochem.2009.07.013
42. **Binkley N, Krueger DC, Morgan S, Wiebe D.** Current status of clinical 25-hydroxyvitamin D measurement: an assessment of between-laboratory agreement. Clin Chim Acta. 2010;411:1976-82. [PMID: 20713030] doi:10.1016/j.cca.2010.08.018
43. **Moon HW, Cho JH, Hur M, Song J, Oh GY, Park CM, et al.** Comparison of four current 25-hydroxyvitamin D assays. Clin Biochem. 2012;45:326-30. [PMID: 22244986] doi:10.1016/j.clinbiochem.2011.12.025
44. **Carter GD.** Accuracy of 25-hydroxyvitamin D assays: confronting the issues. Curr Drug Targets. 2011;12:19-28. [PMID: 20795940]
45. **Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al.** The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab. 2011;96:53-8. [PMID: 21118827] doi:10.1210/jc.2010-2704
46. **LeBlanc E, Chou R, Zakher B, Daeges M, Pappas M.** Screening for Vitamin D Deficiency: Systematic Review for the U.S. Preventive Servies Task Force Recommendation [in press]. Rockville, MD: Agency for Healthcare Research and Quality; 2014.
47. **Looker AC, Johnson CL, Lacher DA, Pfeiffer CM, Schleicher RL, Sempos CT.** Vitamin D status: United States, 2001-2006. NCHS Data Brief. 2011:1-8. [PMID: 21592422]
48. **Ginde AA, Liu MC, Camargo CA Jr.** Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch Intern Med. 2009;169:626-32. [PMID: 19307527] doi: 10.1001/archinternmed.2008.604
49. **McCullough ML, Weinstein SJ, Freedman DM, Helzlsouer K, Flanders WD, Koenig K, et al.** Correlates of circulating 25-hydroxyvitamin D: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol. 2010;172:21-35. [PMID: 20562191] doi:10.1093/aje/kwq113

This online-first version will be replaced with a final version when it is included in the issue. The final version may differ in small ways.

50. **Orwoll E, Nielson CM, Marshall LM, Lambert L, Holton KF, Hoffman AR, et al; Osteoporotic Fractures in Men (MrOS) Study Group.** Vitamin D deficiency in older men. J Clin Endocrinol Metab. 2009; 94:1214-22. [PMID: 19174492] doi:10.1210/jc.2008-1784
51. **Forrest KY, Stuhldreher WL.** Prevalence and correlates of vitamin D deficiency in US adults. Nutr Res. 2011;31:48-54. [PMID: 21310306] doi:10.1016/j.nutres.2010.12.001
52. **Jacques PF, Felson DT, Tucker KL, Mahnken B, Wilson PW, Rosenberg IH, et al.** Plasma 25-hydroxyvitamin D and its determinants in an elderly population sample. Am J Clin Nutr. 1997;66:929-36. [PMID: 9322570]
53. **Millen AE, Wactawski-Wende J, Pettinger M, Melamed ML, Tylavsky FA, Liu S, et al.** Predictors of serum 25-hydroxyvitamin D concentrations among postmenopausal women: the Women's Health Initiative calcium plus vitamin D clinical trial. Am J Clin Nutr. 2010; 91:1324-35. [PMID: 20219959] doi:10.3945/ajcn.2009.28908
54. **Linos E, Keiser E, Kanzler M, Sainani KL, Lee W, Vittinghoff E, et al.** Sun protective behaviors and vitamin D levels in the US population: NHANES 2003-2006. Cancer Causes Control. 2012;23:133-40. [PMID: 22045154] doi:10.1007/s10552-011-9862-0
55. **Samuel L, Borrell LN.** The effect of body mass index on optimal vitamin D status in U.S. adults: the National Health and Nutrition Examination Survey 2001-2006. Ann Epidemiol. 2013;23:409-14. [PMID: 23790345] doi:10.1016/j.annepidem.2013.05.011
56. **Rejnmark L, Avenell A, Masud T, Anderson F, Meyer HE, Sanders KM, et al.** Vitamin D with calcium reduces mortality: patient level pooled analysis of 70,528 patients from eight major vitamin D trials. J Clin Endocrinol Metab. 2012;97:2670-81. [PMID: 22605432] doi: 10.1210/jc.2011-3328
57. **DIPART (Vitamin D Individual Patient Analysis of Randomized Trials) Group.** Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe. BMJ. 2010; 340:b5463. [PMID: 20068257] doi:10.1136/bmj.b5463
58. **Jones G.** Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr. 2008;88:582S-586S. [PMID: 18689406]
59. **Vieth R.** Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr. 1999;69:842-56. [PMID: 10232622]
60. **Moyer VA; U.S. Preventive Services Task Force.** Prevention of falls in community-dwelling older adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157: 197-204. [PMID: 22868837]
61. **U.S. Preventive Services Task Force.** Vitamin D and Calcium Supplementation to Prevent Cancer and Osteoporotic Fractures in Adults: Draft Recommendation Statement. Rockville, MD: U.S. Preventive Services Task Force; 2014.
62. **U.S. Preventive Services Task Force.** Final Recommendation Statement: Vitamin D and Calcium to Prevent Fractures: Preventive Medication. Rockville, MD: U.S. Preventive Services Task Force; 2014. Accessed at www.uspreventiveservicestaskforce.org/uspstf12/vitamind/finalrecvitd.htm on 17 January 2014.
63. **U.S. Preventive Services Task Force.** Final Recommendation Statement: Vitamin Supplementation to Prevent Cancer and CVD: Counseling. Rockville, MD: U.S. Preventive Services Task Force; 2014. Accessed at www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/vitamin-supplementation-to-prevent-cancer-and-cvd-counseling on 5 November 2014.
64. **Jackson RD, LaCroix AZ, Cauley JA, McGowan J.** The Women's Health Initiative calcium-vitamin D trial: overview and baseline characteristics of participants. Ann Epidemiol. 2003;13:S98-106. [PMID: 14575942]
65. **U.S. Preventive Services Task Force.** Procedure Manual. AHRQ publication no. 08-05118-EF. December 2013. Accessed at www.uspreventiveservicestaskforce.org/uspstf08/methods/procmanual.htm on 3 April 2013.
66. **Hardy RJ, Thompson SG.** A likelihood approach to meta-analysis with random effects. Stat Med. 1996;15:619-29. [PMID: 8731004]
67. **Higgins JP, Thompson SG, Deeks JJ, Altman DG.** Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60. [PMID: 12958120]
68. **Brazier M, Grados F, Kamel S, Mathieu M, Morel A, Maamer M, et al.** Clinical and laboratory safety of one year's use of a combination calcium + vitamin D tablet in ambulatory elderly women with vitamin D insufficiency: results of a multicenter, randomized, double-blind, placebo-controlled study. Clin Ther. 2005;27:1885-93. [PMID: 16507374]
69. **Chapuy MC, Pamphile R, Paris E, Kempf C, Schlichting M, Arnaud S, et al.** Combined calcium and vitamin D_3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos Int. 2002;13:257-64. [PMID: 11991447]
70. **Gallagher JC, Peacock M, Yalamanchili V, Smith LM.** Effects of vitamin D supplementation in older African American women. J Clin Endocrinol Metab. 2013;98:1137-46. [PMID: 23386641] doi:10.1210/jc.2012-3106
71. **Gallagher JC, Jindal PS, Smith LM.** Vitamin D supplementation in young White and African American women. J Bone Miner Res. 2014; 29:173-81. [PMID: 23761326] doi:10.1002/jbmr.2010
72. **Grimnes G, Figenschau Y, Almås B, Jorde R.** Vitamin D, insulin secretion, sensitivity, and lipids: results from a case-control study and a randomized controlled trial using hyperglycemic clamp technique. Diabetes. 2011;60:2748-57. [PMID: 21911741] doi:10.2337/db11-0650
73. **Lips P, Binkley N, Pfeifer M, Recker R, Samanta S, Cohn DA, et al.** Once-weekly dose of 8400 IU vitamin $D_{(3)}$ compared with placebo: effects on neuromuscular function and tolerability in older adults with vitamin D insufficiency. Am J Clin Nutr. 2010;91:985-91. [PMID: 20130093] doi:10.3945/ajcn.2009.28113
74. **Pfeifer M, Begerow B, Minne HW, Abrams C, Nachtigall D, Hansen C.** Effects of a short-term vitamin D and calcium supplementation on body sway and secondary hyperparathyroidism in elderly women. J Bone Miner Res. 2000;15:1113-8. [PMID: 10841179]
75. **Arvold DS, Odean MJ, Dornfeld MP, Regal RR, Arvold JG, Karwoski GC, et al.** Correlation of symptoms with vitamin D deficiency and symptom response to cholecalciferol treatment: a randomized controlled trial. Endocr Pract. 2009;15:203-12. [PMID: 19364687]
76. **Bischoff HA, Stähelin HB, Dick W, Akos R, Knecht M, Salis C, et al.** Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. J Bone Miner Res. 2003;18:343-51. [PMID: 12568412]
77. **Kärkkäinen M, Tuppurainen M, Salovaara K, Sandini L, Rikkonen T, Sirola J, et al.** Effect of calcium and vitamin D supplementation on bone mineral density in women aged 65-71 years: a 3-year randomized population-based trial (OSTPRE-FPS). Osteoporos Int. 2010;21: 2047-55. [PMID: 20204604] doi:10.1007/s00198-009-1167-8
78. **Kärkkäinen MK, Tuppurainen M, Salovaara K, Sandini L, Rikkonen T, Sirola J, et al.** Does daily vitamin D 800 IU and calcium 1000 mg supplementation decrease the risk of falling in ambulatory women aged 65-71 years? A 3-year randomized population-based trial (OSTPRE-FPS). Maturitas. 2010;65:359-65. [PMID: 20060665] doi:10.1016/j.maturitas.2009.12.018
79. **Kjærgaard M, Waterloo K, Wang CE, Almås B, Figenschau Y, Hutchinson MS, et al.** Effect of vitamin D supplement on depression scores in people with low levels of serum 25-hydroxyvitamin D: nested case-control study and randomised clinical trial. Br J Psychiatry. 2012;201:360-8. [PMID: 22790678] doi:10.1192/bjp.bp.111.104349
80. **Krieg MA, Jacquet AF, Bremgartner M, Cuttelod S, Thiébaud D, Burckhardt P.** Effect of supplementation with vitamin D_3 and calcium on quantitative ultrasound of bone in elderly institutionalized women: a longitudinal study. Osteoporos Int. 1999;9:483-8. [PMID: 10624454]
81. **Lips P, Graafmans WC, Ooms ME, Bezemer PD, Bouter LM.** Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial. Ann Intern Med. 1996;124:400-6. [PMID: 8554248]
82. **Gallagher JC, Sai A, Templin T 2nd, Smith L.** Dose response to vitamin D supplementation in postmenopausal women: a randomized trial. Ann Intern Med. 2012;156:425-37. [PMID: 22431675] doi: 10.7326/0003-4819-156-6-201203200-00005

This online-first version will be replaced with a final version when it is included in the issue. The final version may differ in small ways.

83. **Ooms ME, Roos JC, Bezemer PD, van der Vijgh WJ, Bouter LM, Lips P.** Prevention of bone loss by vitamin D supplementation in elderly women: a randomized double-blind trial. J Clin Endocrinol Metab. 1995;80:1052-8. [PMID: 7714065]
84. **Pfeifer M, Begerow B, Minne HW, Suppan K, Fahrleitner-Pammer A, Dobnig H.** Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals. Osteoporos Int. 2009;20:315-22. [PMID: 18629569] doi:10.1007/s00198-008-0662-7
85. **Wood AD, Secombes KR, Thies F, Aucott L, Black AJ, Mavroeidi A, et al.** Vitamin D_3 supplementation has no effect on conventional cardiovascular risk factors: a parallel-group, double-blind, placebo-controlled RCT. J Clin Endocrinol Metab. 2012;97:3557-68. [PMID: 22865902] doi:10.1210/jc.2012-2126
86. **Chlebowski RT, Johnson KC, Kooperberg C, Pettinger M, Wactawski-Wende J, Rohan T, et al; Women's Health Initiative Investigators.** Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst. 2008;100:1581-91. [PMID: 19001601] doi:10.1093/jnci/djn360
87. **de Boer IH, Tinker LF, Connelly S, Curb JD, Howard BV, Kestenbaum B, et al; Women's Health Initiative Investigators.** Calcium plus vitamin D supplementation and the risk of incident diabetes in the Women's Health Initiative. Diabetes Care. 2008;31:701-7. [PMID: 18235052] doi:10.2337/dc07-1829
88. **Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, et al; Women's Health Initiative Investigators.** Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006;354:669-83. [PMID: 16481635]
89. **LaCroix AZ, Kotchen J, Anderson G, Brzyski R, Cauley JA, Cummings SR, et al.** Calcium plus vitamin D supplementation and mortality in postmenopausal women: the Women's Health Initiative calcium-vitamin D randomized controlled trial. J Gerontol A Biol Sci Med Sci. 2009;64:559-67. [PMID: 19221190] doi:10.1093/gerona/glp006
90. **Wactawski-Wende J, Kotchen JM, Anderson GL, Assaf AR, Brunner RL, O'Sullivan MJ, et al; Women's Health Initiative Investigators.** Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med. 2006;354:684-96. [PMID: 16481636]
91. **Williams DA, Arnold LM.** Measures of fibromyalgia: Fibromyalgia Impact Questionnaire (FIQ), Brief Pain Inventory (BPI), Multidimensional Fatigue Inventory (MFI-20), Medical Outcomes Study (MOS) Sleep Scale, and Multiple Ability Self-Report Questionnaire (MASQ). Arthritis Care Res (Hoboken). 2011;63 Suppl 11:S86-97. [PMID: 22588773] doi:10.1002/acr.20531
92. **Aloia JF, Patel M, Dimaano R, Li-Ng M, Talwar SA, Mikhail M, et al.** Vitamin D intake to attain a desired serum 25-hydroxyvitamin D concentration. Am J Clin Nutr. 2008;87:1952-8. [PMID: 18541590]
93. **Aloia JF, Talwar SA, Pollack S, Yeh J.** A randomized controlled trial of vitamin D_3 supplementation in African American women. Arch Intern Med. 2005;165:1618-23. [PMID: 16043680]
94. **Harris SS, Dawson-Hughes B, Perrone GA.** Plasma 25-hydroxyvitamin D responses of younger and older men to three weeks of supplementation with 1800 IU/day of vitamin D. J Am Coll Nutr. 1999;18:470-4. [PMID: 10511329]
95. **Talwar SA, Aloia JF, Pollack S, Yeh JK.** Dose response to vitamin D supplementation among postmenopausal African American women. Am J Clin Nutr. 2007;86:1657-62. [PMID: 18065583]
96. **Berlin T, Emtestam L, Björkhem I.** Studies on the relationship between vitamin D3 status and urinary excretion of calcium in healthy subjects: effects of increased levels of 25-hydroxyvitamin D_3. Scand J Clin Lab Invest. 1986;46:723-9. [PMID: 3026026]
97. **Honkanen R, Alhava E, Parviainen M, Talasniemi S, Mönkkönen R.** The necessity and safety of calcium and vitamin D in the elderly. J Am Geriatr Soc. 1990;38:862-6. [PMID: 2387950]
98. **Janssen HC, Samson MM, Verhaar HJ.** Muscle strength and mobility in vitamin D-insufficient female geriatric patients: a randomized controlled trial on vitamin D and calcium supplementation. Aging Clin Exp Res. 2010;22:78-84. [PMID: 20305368]
99. **Lehmann U, Hirche F, Stangl GI, Hinz K, Westphal S, Dierkes J.** Bioavailability of vitamin $D_{(2)}$ and $D_{(3)}$ in healthy volunteers, a randomized placebo-controlled trial. J Clin Endocrinol Metab. 2013;98:4339-45. [PMID: 24001747] doi:10.1210/jc.2012-4287
100. **Martineau AR, Wilkinson RJ, Wilkinson KA, Newton SM, Kampmann B, Hall BM, et al.** A single dose of vitamin D enhances immunity to mycobacteria. Am J Respir Crit Care Med. 2007;176:208-13. [PMID: 17463418]
101. **Wamberg L, Kampmann U, Stødkilde-Jørgensen H, Rejnmark L, Pedersen SB, Richelsen B.** Effects of vitamin D supplementation on body fat accumulation, inflammation, and metabolic risk factors in obese adults with low vitamin D levels–results from a randomized trial. Eur J Intern Med. 2013;24:644-9. [PMID: 23566943] doi:10.1016/j.ejim.2013.03.005
102. **Wamberg L, Pedersen SB, Richelsen B, Rejnmark L.** The effect of high-dose vitamin D supplementation on calciotropic hormones and bone mineral density in obese subjects with low levels of circulating 25-hydroxyvitamin d: results from a randomized controlled study. Calcif Tissue Int. 2013;93:69-77. [PMID: 23591713] doi:10.1007/s00223-013-9729-3
103. **Knutsen KV, Madar AA, Lagerløv P, Brekke M, Raastad T, Stene LC, et al.** Does vitamin D improve muscle strength in adults? A randomized, double-blind, placebo-controlled trial among ethnic minorities in Norway. J Clin Endocrinol Metab. 2014;99:194-202. [PMID: 24248184] doi:10.1210/jc.2013-2647
104. **Chung M, Lee J, Terasawa T, Lau J, Trikalinos TA.** Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;155:827-38. [PMID: 22184690] doi:10.7326/0003-4819-155-12-201112200-00005
105. **Michael YL, Whitlock EP, Lin JS, Fu R, O'Connor EA, Gold R; US Preventive Services Task Force.** Primary care-relevant interventions to prevent falling in older adults: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2010;153:815-25. [PMID: 21173416] doi:10.7326/0003-4819-153-12-201012210-00008
106. **Fortmann SP, Burda BU, Senger CA, Lin JS, Whitlock EP.** Vitamin and mineral supplements in the primary prevention of cardiovascular disease and cancer: an updated systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2013;159:824-34. [PMID: 24217421]
107. **Cornell JE, Mulrow CD, Localio R, Stack CB, Meibohm AR, Guallar E, et al.** Random-effects meta-analysis of inconsistent effects: a time for change. Ann Intern Med. 2014;160:267-70. [PMID: 24727843]
108. **Ott SM, Chesnut CH 3rd.** Calcitriol treatment is not effective in postmenopausal osteoporosis. Ann Intern Med. 1989;110:267-74. [PMID: 2913914]
109. **Orwoll ES, McClung MR, Oviatt SK, Recker RR, Weigel RM.** Histomorphometric effects of calcium or calcium plus 25-hydroxyvitamin D_3 therapy in senile osteoporosis. J Bone Miner Res. 1989;4:81-8. [PMID: 2718782]
110. **Mastaglia SR, Mautalen CA, Parisi MS, Oliveri B.** Vitamin D_2 dose required to rapidly increase 25OHD levels in osteoporotic women. Eur J Clin Nutr. 2006;60:681-7. [PMID: 16391587]
111. **Bischoff-Ferrari HA, Dawson-Hughes B, Platz A, Orav EJ, Stähelin HB, Willett WC, et al.** Effect of high-dosage cholecalciferol and extended physiotherapy on complications after hip fracture: a randomized controlled trial. Arch Intern Med. 2010;170:813-20. [PMID: 20458090] doi:10.1001/archinternmed.2010.67
112. **Prince RL, Austin N, Devine A, Dick IM, Bruce D, Zhu K.** Effects of ergocalciferol added to calcium on the risk of falls in elderly high-risk women. Arch Intern Med. 2008;168:103-8. [PMID: 18195202] doi:10.1001/archinternmed.2007.31
113. **Zhu K, Bruce D, Austin N, Devine A, Ebeling PR, Prince RL.** Randomized controlled trial of the effects of calcium with or without vitamin D on bone structure and bone-related chemistry in elderly women with vitamin D insufficiency. J Bone Miner Res. 2008;23:1343-8. [PMID: 18410225] doi:10.1359/jbmr.080327
114. **Latham NK, Anderson CS, Lee A, Bennett DA, Moseley A, Cameron ID; Fitness Collaborative Group.** A randomized, controlled trial of quadriceps resistance exercise and vitamin D in frail older people:

This online-first version will be replaced with a final version when it is included in the issue. The final version may differ in small ways.


the Frailty Interventions Trial in Elderly Subjects (FITNESS). J Am Geriatr Soc. 2003;51:291-9. [PMID: 12588571]
115. **Gloth FM 3rd, Smith CE, Hollis BW, Tobin JD.** Functional improvement with vitamin D replenishment in a cohort of frail, vitamin D-deficient older people. J Am Geriatr Soc. 1995;43:1269-71. [PMID: 7594162]
116. **Corless D, Dawson E, Fraser F, Ellis M, Evans SJ, Perry JD, et al.** Do vitamin D supplements improve the physical capabilities of elderly hospital patients? Age Ageing. 1985;14:76-84. [PMID: 4003187]
117. **Davidson MB, Duran P, Lee ML, Friedman TC.** High-dose vitamin D supplementation in people with prediabetes and hypovitaminosis D. Diabetes Care. 2013;36:260-6. [PMID: 23033239] doi: 10.2337/dc12-1204
118. **Witham MD, Crighton LJ, Gillespie ND, Struthers AD, McMurdo ME.** The effects of vitamin D supplementation on physical function and quality of life in older patients with heart failure: a randomized controlled trial. Circ Heart Fail. 2010;3:195-201. [PMID: 20103775] doi:10.1161/CIRCHEARTFAILURE.109.907899
119. **Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R.** Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr. 2006;83:754-9. [PMID: 16600924]
120. **Martineau AR, Timms PM, Bothamley GH, Hanifa Y, Islam K, Claxton AP, et al.** High-dose vitamin $D_{(3)}$ during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet. 2011;377:242-50. [PMID: 21215445] doi:10.1016/S0140-6736(10)61889-2
121. **Vieth R.** What is the optimal vitamin D status for health? Prog Biophys Mol Biol. 2006;92:26-32. [PMID: 16766239]
122. **National Osteoporosis Foundation.** Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2010. Accessed at http://nof.org/files/nof/public/content/file/344/upload/159.pdf on 5 November 2014.
123. **Dawson-Hughes B, Cooper C; International Osteoporosis Foundation.** IOF statement of new IOM dietary reference intakes for calcium and vitamin D. Accessed at www.iofbonehealth.org/iof-statement-new-iom-dietary-reference-intakes-calcium-and-vitamin-d on 5 November 2014.
124. **Dawson-Hughes B, Mithal A, Bonjour JP, Boonen S, Burckhardt P, Fuleihan GE, et al.** IOF position statement: vitamin D recommendations for older adults. Osteoporos Int. 2010;21:1151-4. [PMID: 20422154] doi:10.1007/s00198-010-1285-3

This online-first version will be replaced with a final version when it is included in the issue. The final version may differ in small ways.

Current Author Addresses: Dr. LeBlanc: Center for Health Research, Kaiser Permanente, 3800 North Interstate Avenue, Portland, OR 97227.
Ms. Zakher, Ms. Daeges, Ms. Pappas, and Dr. Chou: Oregon Health and Science University, 3181 Southwest Sam Jackson Park Road, Mail code: BICC, Portland, OR 97239.

Author Contributions: Conception and design: E.S. LeBlanc, B. Zakher, M. Pappas, R. Chou.
Analysis and interpretation of the data: E.S. LeBlanc, B. Zakher, M. Pappas, R. Chou.
Drafting of the article: E.S. LeBlanc, M. Pappas, R. Chou.
Critical revision of the article for important intellectual content: E.S. LeBlanc, M. Pappas, R. Chou.
Final approval of the article: E.S. LeBlanc, M. Pappas, R. Chou.
Provision of study materials or patients: M. Daeges.
Statistical expertise: R. Chou.
Obtaining of funding: R. Chou.
Administrative, technical, or logistic support: M. Daeges, M. Pappas.
Collection and assembly of data: B. Zakher, M. Daeges, M. Pappas, R. Chou.


Appendix Figure 1. Analytic framework.



Numbers on figures indicate key questions. For a list of key questions, see Methods.

This online-first version will be replaced with a final version when it is included in the issue. The final version may differ in small ways.

Appendix Figure 2. Summary of evidence search and selection.



* Cochrane Central Register of Controlled Trials and the Cochrane Database of Systematic Reviews.
† Identified from reference lists, hand searching, or suggested by experts.
‡ Studies that provided data and contributed to the body of evidence were considered included. Studies may have provided data for more than 1 key question or published article; 27 unique studies were included, and a total of 35 articles were included.

This online-first version will be replaced with a final version when it is included in the issue. The final version may differ in small ways.

Appendix Table. Studies of Effectiveness and Harms of Vitamin D Treatment

Study, Year (Reference)	Quality	Country	Population Characteristics*	25-(OH)D Level at Baseline, *ng/mL**†‡	25-(OH)D Level at Follow-up, *ng/mL**†‡	Intervention	Duration*	Clinical Health Outcomes Reported	AEs/Harms Reported
25-(OH)D level <50 nmol/L§									
Brazier et al, 2005 (68)	Fair	France	Analyzed: 191 Age: 74.6 y Female: 100% Comorbid conditions: NR History of falls: NR Institutionalized: 0%	7 vs. 7	Median: 29 vs. 11	Vitamin D group (*n* = 95): Vitamin D_3, 800 IU/d, and calcium, 1000 mg/d Control group (*n* = 96): Placebo	12 mo	Death	Total AEs; withdrawal due to AEs; serious AEs; any AE; hypercalcemia; and GI, osteomuscular, nervous system, and metabolic/nutritional AEs
Chapuy et al, 2002 (69)	Fair	France	Analyzed: 583 Age: 85 y Female: 100% Comorbid conditions: NR History of falls: 16.1% Use of walking device: 40.7% Institutionalized: 100%	9 vs. 9	≅33 vs. 5; *P* <0.001 for change from baseline for vitamin D group only‖	Vitamin D group (*n* = 393): Vitamin D_3, 800 IU/d, and calcium, 1200 mg/d Control group (*n* = 190): Placebo	24 mo	Fractures¶, persons who fell, and death	Withdrawal due to AEs (NR by group), hypercalcemia, kidney stones, hypercalciuria, and GI AEs
Gallagher et al, 2013 (70)	Fair	United States	Analyzed: 110 Age: 67 y Female: 100% BMI: 32.7 kg/m^2 Comorbid conditions: NR History of falls: NR Institutionalized: NR	Placebo: 14 Vitamin D: 800 IU/d: 14 1600 IU/d: 13 2400 IU/d: 14 4800 IU/d: 14 400, 3600, or 4000 IU/d: NR	97.5% of those receiving vitamin D, 800 IU/d, reached 25-(OH)D levels >20 ng/mL; *P* <0.05 vs. placebo for all vitamin D groups‖	Vitamin D group: Vitamin D_3, 400, 800, 1600, 2400, 3200, 4000, or 4800 IU/d Control group: Placebo All participants: Supplements to maintain total calcium intake of 1200–1400 mg/d	12 mo	Death**	Withdrawal due to AEs**, serious AEs, and hypercalcemia
Gallagher et al, 2014 (71)	Fair	United States	Analyzed: 198 Age: 37 y Female: 100% BMI: 30.2 kg/m^2 Comorbid conditions: NR History of falls: NR Institutionalized: NR	Placebo: 13 Vitamin D: 400 IU/d: 13 800 IU/d: 14 1600 IU/d: 13 2400 IU/d: 14	97.5% of white women receiving vitamin D, 400 IU/d, reached 25-(OH)D levels >20 ng/mL 97.5% of black women receiving vitamin D, 800–1600 IU/d, reached 25-(OH)D levels >20 ng/mL‖	Vitamin D group: Vitamin D_3, 400, 800, 1600, or 2400 IU/d Control group: Placebo All participants: Supplements to maintain total calcium intake of 1000–1200 mg/d	12 mo	Death**	Serious AEs (NR by group), hypercalcemia, and kidney stones
Grimnes et al, 2011 (72)	Fair	Norway	Analyzed: 104 Age: 52.1 y Vitamin D group: 51.5 y Control group: 52.7 y Female: 49.1% Vitamin D group: 45.0% Control group: 51.0% BMI: 26.5 kg/m^2 Vitamin D group: 27.2 kg/m^2 Control group: 26.3 kg/m^2 History of falls: NR Institutionalized: 0%	17 vs. 16	57 vs. 17	Vitamin D group (*n* = 51): Vitamin D_3, 40 000 IU/wk Control group (*n* = 53): Placebo	6 mo	Death	Total AEs, hypercalcemia, and kidney stones
Janssen et al, 2010 (98)	Fair	Netherlands	Analyzed: 59 Age: 80.8 y† Female: 100% BMI: 26.4 kg/m^2† Comorbid conditions: 2.4† Medications used: 5.0† History of falls: NR Institutionalized: 100%††	13 vs. 14	31 vs. 17	Vitamin D group (*n* = 28): Vitamin D_3, 400 IU/d, and calcium, 500 mg/d Control group (*n* = 31): Placebo and calcium, 500 mg/d	6 mo	NR	Withdrawals and any AE
Knutsen et al, 2014 (103)	Fair	Norway	Analyzed: 215 Age: 37.3 y† Female: 73% BMI: 27.4 kg/m^2† Comorbid conditions: NR History of falls: NR Institutionalized: NR	11 vs. 11	19 vs. 10	Vitamin D group (*n* = 144): Vitamin D_3, 25 or 10 mcg/d Control group (*n* = 71): Placebo	16 wk	NR	Total AEs
Lips et al, 2010 (73)	Fair	Netherlands, Germany, and United States	Analyzed for SPPB: 213 Analyzed for death: 226 Age: 78 y Female: NR BMI: 27.8 kg/m^2† Comorbid conditions: NR History of falls: NR Use of walking device: 15% Institutionalized: 14%	14 vs. 14	26 vs. 12; *P* <0.001	Vitamin D group (*n* = 114): Vitamin D_3, 8400 IU/wk Control group (*n* = 112): Placebo All participants: Those with calcium intake <1000 mg/d also received calcium, 500 mg/d	16 wk	Physical function and death	Withdrawal due to AEs, serious AEs, any AE, kidney stones, and hypercalcemia‡‡

Continued on following page

Appendix Table–Continued

Study, Year (Reference)	Quality	Country	Population Characteristics*	25-(OH)D Level at Baseline, *ng/mL**†‡	25-(OH)D Level at Follow-up, *ng/mL**†‡	Intervention	Duration*	Clinical Health Outcomes Reported	AEs/Harms Reported
Pfeifer et al, 2000 (74)	Fair	Germany	Analyzed: 137 Age: 74.8 y† Female: 100% BMI: 25.5 kg/m^2† Comorbid conditions: Cardiovascular: 39% CNS or neurologic: 12% Psychiatric: <1% Musculoskeletal: 22% History of falls: NR Use of walking device: NR Institutionalized: 0%	10 vs. 10	26 vs. 17; P <0.001	Vitamin D group (n = 70): Vitamin D_3, 800 IU/d, and calcium, 1200 mg/d Control group (n = 67): Calcium, 1200 mg/d	Treatment: 8 wk Follow-up: 1 y	Falls, persons who fell, and fractures	NR
Wamberg et al, 2013 (101, 102)	Fair	Denmark	Analyzed: 43 Age: 40.5 y Female: 71% BMI: 35.8 kg/m^2† Sedentary: 35%† Lightly active: 48%† Moderately active: 17%† Comorbid conditions: Receiving lipid-lowering medications: 2% (1/55) Receiving antihypertensive medications: 5% (3/55) History of falls: NR Institutionalized: NR	14 vs. 14	44 vs. 19	Vitamin D group (n = 22): Vitamin D_3, 7000 IU/d Control group (n = 21): Placebo	26 wk	NR	Total AEs and hypercalcemia
25-(OH)D level ≤75 nmol/L§§									
Aloia et al, 2008 (92)	Fair	United States	Analyzed: 138 Age: 47.2 y† Female: 81% History of falls: NR Institutionalized: NR	19 overall	>30 ng/mL achieved by virtually all in the active group; also increased by 8 ng/mL in the placebo group because of seasonal change	Vitamin D group (n = 65): Vitamin D_3 dose was dependent on 25-(OH)D levels; mean dosage, 3440 IU/d Control group (n = 73): Placebo	6 mo	NR	Hypercalcemia and hypercalciuria
Arvold et al, 2009 (75)	Fair	United States	Analyzed: 90 Age: 58.8 y† Female: 40% BMI: NR Comorbid conditions: NR History of falls: NR Use of walking device: NR Institutionalized: 0%	18 vs. 18	45 vs. 22	Vitamin D group (n = 48): Vitamin D_3, 50 000 IU/wk Control group (n = 42): Placebo	8 wk	Psychosocial function and disability	Any AE
Berlin et al, 1986 (96)	Poor	Sweden	Analyzed: 24 Age: 31 y (range, 22–47 y) Female: 0% History of falls: NR Institutionalized: NR	15 vs. 15	49 vs. 19	Vitamin D group (n = 12): Vitamin D_3, 54 000 IU/wk Control group (n = 12): No treatment	NR|||	NR	Any AE
Bischoff et al, 2003 (76)	Fair	Switzerland	Analyzed: 122 Age: 85 y Female: 100% BMI: 24.7 kg/m^2 Comorbid conditions: Hypertension: 30.3% Stroke: 15.6% MI or CHF: 50.0% Anemia: 12.3% Diabetes: 14.8% COPD: 8.2% Peptic ulcer disease: 16.4% Depression: 24.6% Malnutrition: 9.0% Obesity: 4.1% Dementia: 54.9% Fracture at any site: 54.1% History of falls: 34% Use of walking device: 60% Institutionalized: 100%	Median: 12 vs. 12	Median: 26 vs. 11; P <0.001	Vitamin D group (n = 62): Vitamin D_3, 800 IU/d, and calcium, 1200 mg/d Control group (n = 60): Calcium, 1200 mg/d	Pretreatment: 6 wk Treatment: 12 wk	Falls¶	Hypercalcemia, withdrawals, and GI AEs

Continued on following page

This online-first version will be replaced with a final version when it is included in the issue. The final version may differ in small ways.

Appendix Table–Continued

Study, Year (Reference)	Quality	Country	Population Characteristics*	25-(OH)D Level at Baseline, *ng/mL**†‡	25-(OH)D Level at Follow-up, *ng/mL**†‡	Intervention	Duration*	Clinical Health Outcomes Reported	AEs/Harms Reported
Gallagher et al, 2012 (82)	Good	United States	Analyzed: 163 Age: 67 y Female: 100% BMI: 30.2 kg/m^2 Comorbid conditions: NR History of falls: NR Institutionalized: NR	Placebo: 15 Vitamin D: 400 IU/d: 15 800 IU/d: 16 1600 IU/d: 15 2400 IU/d: 15 3200 IU/d: 16 4000 IU/d: 15 4800 IU/d: 16	97.5% of those receiving vitamin D, 600 IU/d, reached 25-(OH)D levels >20 ng/mL; P <0.05 vs. placebo for all vitamin D groups‖	Vitamin D group (n = 142): Vitamin D_3, 400, 800, 1600, 2400, 3200, 4000, or 4800 IU/d Control group (n = 21): Placebo All participants: Supplements to maintain total calcium intake of 1200–1400 mg/d	Median: 12 mo	Death	Withdrawal due to AEs, any AE, serious AEs, kidney stones, and hypercalcemia
Harris et al, 1999 (94)	Poor	United States	Analyzed: 18 Age: 31 y (range, 22–47 y) Female: 0% Comorbid conditions: NR History of falls: NR Institutionalized: NR	Younger men: 13 vs. 17 Older men: 16 vs. 16	Younger men: 25 vs. 13 Older men: 19 vs. 15	Vitamin D group (n = 11): Vitamin D_2, 1800 IU/d Control group (n = 7): No treatment	3 wk	NR	Any AE
Honkanen et al, 1990 (97)	Fair	Finland	Analyzed: 126 Home patients: Age: 69.5 y† Female: 100% Weight: 69.5 kg† Comorbid conditions: NR History of falls: NR Hospital inpatients (52%): Age: 82.5 y† Female: 100% Weight: 61.8 kg† Comorbid conditions: NR History of falls: NR	Home patients: 17 vs. 15 Hospital inpatients: 10 vs. 10	Home patients: 32 vs. 9 Hospital inpatients: 26 vs. 4	Vitamin D group (n = 63): Vitamin D_3, 1800 IU/d, and calcium, 1.558 g/d Control (n = 63): No treatment	11 wk	NR	Hypercalcemia and kidney stones
Kärkkäinen et al, 2010 (77, 78)	Fair	Finland	Analyzed: 593 Age: 67.4 y† Female: 100% BMI: 27.5 kg/m^2† Comorbid conditions: NR History of falls: NR Ambulatory: 100% Institutionalized: NR	20 vs. 20	30 vs. 22	Vitamin D group (n = 290 for death outcomes and 287 for fall/persons who fell outcomes): Vitamin D_3, 800 IU/d, and calcium, 1000 mg/d Control group (n = 313 for death outcomes and 306 for fall/persons who fell outcomes): No treatment	3 y	Falls¶, persons who fell, and death	Withdrawal due to AEs
Kjærgaard et al, 2012 (79)	Good	Norway	Analyzed: 230¶¶ Age: 53.4 y† Female: 56% BMI: 27.7 kg/m^2† Comorbid conditions: NR History of falls: NR Institutionalized: NR	19 vs. 19	59 vs. 21	Vitamin D group (n = 120): Vitamin D_3, 20 000 IU/wk Control group (n = 110): Placebo	6 mo	Psychosocial function¶	Hypercalcemia; total AEs; and GI, respiratory, dermatologic, musculoskeletal, urogenital, circulatory, neurologic, endocrine, and other organ AEs
Krieg et al, 1999 (80)	Fair	Switzerland	Analyzed: 248 Age: 84.5 y† Female: 100% BMI: 24.7 kg/m^2† History of falls: NR Institutionalized: 100%	12 vs. 12	27 vs. 6	Vitamin D group (n = 124): Vitamin D_3, 880 IU/d, and calcium, 1000 mg/d Control group (n = 124): No supplementation	2 y	Death	Withdrawal due to AEs
Lips et al, 1996 (81), and Ooms et al, 1995 (83)	Fair	Netherlands	Analyzed for fracture: 270 Analyzed for death: 348 Age: 80.4 y† Female: 100% BMI: 28.3 kg/m^2† Comorbid conditions: NR History of falls: NR Use of walking device: NR Institutionalized: 100%††	Median: 11 vs. 10	Median: 25 vs. 9 (at 1 y)	Vitamin D group (n = 177): Vitamin D_3, 400 IU/d Control group (n = 171): Placebo	3.0–3.5 y; maximum 4 y	Fractures¶ and death	Any AE and hypercalcemia

Continued on following page

This online-first version will be replaced with a final version when it is included in the issue. The final version may differ in small ways.

Appendix Table–Continued

Study, Year (Reference)	Quality	Country	Population Characteristics*	25-(OH)D Level at Baseline, *ng/mL**†‡	25-(OH)D Level at Follow-up, *ng/mL**†‡	Intervention	Duration*	Clinical Health Outcomes Reported	AEs/Harms Reported
Lehmann et al, 2013 (99)	Fair	Norway	Analyzed: 107 Age: 33.8 y† Female: 63.5% BMI: 23.8 kg/m^2† History of falls: NR Institutionalized: NR	Overall: 16 Vitamin D_2 vs. vitamin D_3 vs. control: 15 vs. 18 vs. 16	Vitamin D_2 vs. vitamin D_3 vs. control: 27 vs. 36 vs. 13	Vitamin D group (n = 42, 46: Vitamin D_2 or D_3, 2000 IU/d Control group (n = 19): Placebo	8 wk	NR	Any AE and hypercalcemia
Martineau et al, 2007 (100)	Fair	United Kingdom	Analyzed: 192*** Median age: 33.7 y† Female: 51.2%† History of falls: NR Institutionalized: NR	14 vs. NR	27 vs. NR	Vitamin D group (n = 96): Single dose of vitamin D_2, 100 000 IU Control group (n = 96): Placebo	6 wk	NR	Any AE and hypercalcemia
Pfeifer et al, 2009 (84)	Fair	Austria and Germany	Analyzed: 242 Age: 76.5 y Female: 74.5% BMI: 27.3 kg/m^2 Comorbid conditions: NR History of falls: NR Ambulatory: 100% Institutionalized: 0%	22 vs. 22	Month 12: 34 vs. 23 Month 20: 19 vs. 15	Vitamin D group (n = 122): Vitamin D_3, 800 IU/d, and calcium, 1000 mg/d Control group (n = 120): Calcium, 1000 mg/d	Treatment: 12 mo Posttreatment: 8 mo	Falls¶, persons who fell, and fractures	NR
Talwar et al, 2007 (95), and Aloia et al, 2005 (93)	Fair	United States	Analyzed: 208 Age: 60.5 y† Female: 100% BMI: Vitamin D group: 29 kg/m^2 Control group: 30 kg/m^2 History of falls: NR Institutionalized: NR	19 vs. 17	35 vs. 18	Vitamin D group (n = 104): Vitamin D_3, 800 IU/d, for first 24 mo increased to 2000 IU/d Control group (n = 104): Placebo All participants: Supplements to maintain total calcium intake of 1200–1500 mg/d	36 mo	NR	Total AEs (NR by group), serious AEs, hypercalcemia, hypercalciuria, and kidney stones
Wood et al, 2012 (85)	Fair	United Kingdom	Analyzed: 305 Age: 63.8 y† Female: 100% BMI: 26.7 kg/m^2† History of falls: NR Institutionalized: NR	Vitamin D, 400 IU/d, vs. vitamin D, 1000 IU/d, vs. control: 13 vs. 13 vs. 14	Vitamin D, 400 IU/d, vs. vitamin D, 1000 IU/d, vs. control: 26 vs. 30 vs. 13	Vitamin D group (n = 102): Vitamin D_3, 400 IU/d Vitamin D group (n = 101): Vitamin D_3, 1000 IU/d Control group (n = 102): Placebo	Treatment: 12 mo Follow-up: 1 mo	Falls and type 2 diabetes	Hypercalcemia, total AEs, serious AEs, and GI and osteomuscular AEs

Continued on following page

This online-first version will be replaced with a final version when it is included in the issue. The final version may differ in small ways.

Appendix Table–Continued

Study, Year (Reference)	Quality	Country	Population Characteristics*	25-(OH)D Level at Baseline, *ng/mL**†‡	25-(OH)D Level at Follow-up, *ng/mL**†‡	Intervention	Duration*	Clinical Health Outcomes Reported	AEs/Harms Reported
Entire WHI calcium-vitamin D trial: Jackson et al, 2003 (64) Associated case–control studies with outcome reported: Fracture: Jackson et al, 2006 (88) CRC: Wactawski-Wende et al, 2006 (90) Breast cancer: Chlebowski et al, 2008 (86) Diabetes: de Boer et al, 2008 (87) Death: LaCroix et al, 2009 (89)	Fair	United States	Entire WHI calcium-vitamin D trial Analyzed: 36 282 Age: 62 y Female: 100% BMI: 29 kg/m^2 Race: White: 83.1% Black: 9.1% Hispanic: 4.2% American Indian or Native American: 0.42% Asian or Pacific Islander: 2.0% Unknown or not identified: 1.2% Comorbid conditions in past 12 mo: Previous fracture: 35% No falls: 67% 1 fall: 20% 2 falls: 9.0% >3 falls 4.0% Case–control studies: Comorbid conditions: Fracture: 1491 case patients/control participants CRC: 612 case patients/control participants Breast cancer: 895 case patients/control participants Diabetes: 192 case patients/2905 control participants Death: 323 case patients/1962 control participants Case patient and control participant characteristics: NR	Entire WHI calcium-vitamin D trial: NR Case–control studies: Fracture: <24 CRC: <23 Breast cancer: <27 Diabetes: <24 Death: <21	Entire WHI calcium-vitamin D trial: After 2 y, in a random sample of 1.2% of participants, 25-(OH)D levels were 28% higher (9 ng/mL) in the vitamin D vs. placebo group Case–control studies: NR	Vitamin D group: Vitamin D_3, 400 IU/d, plus calcium, 1000 mg/d Control group: Placebo†††	7 y	Fractures, death, type 2 diabetes, and cancer	NR

25-(OH)D = 25-hydroxyvitamin D; AE = adverse event; BMI = body mass index; CHF = congestive heart failure; CNS = central nervous system; COPD = chronic obstructive pulmonary disease; CRC = colorectal cancer; GI = gastrointestinal; MI = myocardial infarction; NR = not reported; SPPB = Short Physical Performance Battery; WHI = Women's Health Initiative.

* Data are means unless otherwise indicated.

† Calculated.

‡ Vitamin D vs. control group unless otherwise indicated. To convert ng/mL to nmol/L, divide by 0.40.

§ ≥90% of participants had 25-(OH)D levels <50 nmol/L.

‖ Data estimated from a figure found in the study.

¶ Primary outcome.

** Gallagher JC. Personal communication.

†† Received care but not as much as in a nursing home setting.

‡‡ Data not shown.

§§ ≥90% of study participants had 25-(OH)D levels ≤75 nmol/L, with ≥10% with levels ≥50 nmol/L.

‖‖ Implies 2 mo.

¶¶ Per protocol.


*** Population characteristics reported only for those who finished study (n = 131).

††† Number analyzed in case–control studies per intervention (vitamin D vs. control): fractures: 266 vs. 285, CRC: 237 vs. 222, breast cancer: 909 vs. 722, diabetes: 1118 vs. 1187, and death: 675 vs. 678.

This online-first version will be replaced with a final version when it is included in the issue. The final version may differ in small ways.

This online-first version will be replaced with a final version when it is included in the issue. The final version may differ in small ways.

Appendix Figure 3. Meta-analysis of effects of vitamin D treatment on mortality.



To convert ng/mL to nmol/L, divide by 0.40. 25-(OH)D = serum 25-hydroxyvitamin D.
* ≥90% of study participants had 25-(OH)D levels <20 ng/mL.
† ≥90% of study participants had 25-(OH)D levels ≤30 ng/mL, and ≥10% had 25-(OH)D levels ≥20 ng/mL.
‡ Included an institutionalized population.
§ This is a nested case–control study from the Women's Health Initiative calcium-vitamin D trial (64).